Abstract: The present invention relates to a method for treating cancer in a subject, comprising the step of administering to a subject in need thereof administering a therapeutically effective dose of a T cell capable of binding a neopeptide that is expressed by a tumor suppressor gene, wherein said neopeptide is derived from a frameshift product of a tumor suppressor gene and wherein the T cell binds to the neopeptide-MHC complex with a half-life (T1/2) of at least 50 s.

Abstract: The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.

Abstract: To allow control over injected genetically engineered cells, it is helpful that the genetically engineered cells express a marker that can be used to detect such cells among a pool of unmodified cells. Some embodiments relate to a marked protein comprising a TCR constant domain and an exogenous amino acid variation that comprises a sequence that is detectable and identifiable within the TCR constant domain. Other embodiments relate to an antibody epitope that is attached to a TCR chain. Both the marked proteins and the antibody epitopes can be used to track genetically engineered cells.

Abstract: Various embodiments are disclosed herein relate to methods for selection of a genetically engineered cell. Some embodiments relate to a cell that is produced with the methods disclosed herein.

Abstract: The disclosure provides a vector which can be used in a method of generating engineered T cells for use in an autologous or allogeneic setting for engineered immunotherapy. The knockdown of endogenous TCR expression through a vector comprising a miRNA cassette allows for engineering of cells that efficiently express a therapeutic TCR.

Abstract: The present disclosure provides methods to recover repertoires of T cell receptors (TCRs). In some embodiments, TCR repertoires are recovered from non-viable samples. In some embodiments, libraries of TCR?? pairs are created. In some embodiments, the methods disclosed are used for cancer immunotherapy or diagnostic purposes.

Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.

Abstract: The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.

Abstract: The present invention provides compositions and methods for immunotherapy in human. The invention includes a B cell receptor like complex expressed in T cells and comprising an extracellular antigen recognition domain, a trans-membrane domain, a CD79?? heterodimer, and a signaling region that controls T cell activation. The extracellular antigen recognition domain and trans-membrane are derived from the same human or humanized B cell receptor and form a single unit in the complex. The signaling region comprises a T cell signaling domain in combination with a co-stimulatory signaling domain. The signaling region is fused to the CD79?? heterodimer. Furthermore, the B cell receptor like complex of the present invention can use a targeting molecule as a bridge between cytotoxic T cells and targeted cells.

Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.